Optain provides cutting-edge AI diagnostics for retina and cardiovascular disease (CVD) screening globally (US, EU, UK, Australia, New Zealand)
Optain combines AI, retinal imaging, and oculomics to enable widespread access to low cost, non-invasive screening for systemic disease
Optain delivers an AI-backed retinal screening platform that enables non-invasive, rapid assessment of eye and cardiovascular conditions via a robotic camera, teleophthalmology, and AI. Optain’s AI product analyzes retinal photos, detecting diseases like diabetic retinopathy, glaucoma, macular degeneration, and systemic cardiovascular risk with high clinical accuracy. Utilizing proprietary datasets and regulatory-approved algorithms, Optain ensures reliable, unbiased performance across diverse populations. The user-friendly design requires little training and integrates smoothly into clinic workflows, enabling point-of-care diagnosis and reducing barriers to preventive health in underserved settings. With instant, actionable results in seconds, Optain supports better patient outcomes, streamlined care coordination, and more efficient clinical decision-making
Outcomes
Optain’s AI retinal screening platform improves access, increases provider revenue and provider and payor quality scores, and delivers scalable preventive care across a broad patient population
Enables higher retinal screening rates by removing referral barriers—critical in the U.S., where uptake is often below 50%
Supports recurring revenue via reimbursable CPT codes for annual screenings and preventive services
Addresses major conditions like diabetes, glaucoma, AMD, and CVD - impacting tens of millions of patients across care settings
Delivers results in under 60 seconds with >90% accuracy across 10+ diseases
